Drug Trial Radar · NCT00337675
Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,771
Actual
Start
Oct 2006
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).
Conditions
- Asthma
Interventions
montelukast sodiumDrug
Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
Comparator: Placebo (unspecified)Drug
Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
montelukast sodiumDrug
Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment PeriodTime frame: 1-year treatment period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.